Open-label, multicenter, phase III extension study of idalopirdine as adjunctive to donepezil for the treatment of mild-moderate alzheimer’s disease
This open-label extension study evaluated the long-term safety and tolerability of idalopirdine 60 mg/day as adjunctive therapy in patients with mild-moderate Alzheimer’s disease (AD). This extension study was a continuation of Studies 1 and 2 of the
Saved in:
| Main Author: | |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
08 January 2019
|
| In: |
Journal of Alzheimer's disease
Year: 2019, Volume: 67, Issue: 1, Pages: 303-313 |
| ISSN: | 1875-8908 |
| DOI: | 10.3233/JAD-180595 |
| Online Access: | Verlag, Volltext: https://doi.org/10.3233/JAD-180595 Verlag: https://content.iospress.com/articles/journal-of-alzheimers-disease/jad180595 
|
| Author Notes: | Lutz Frölich, Alireza Atri, Clive Ballard, Pierre N. Tariot, José Luis Molinuevo, Neli Boneva, Marie A. Geist, Lars L. Raket, Jeffrey L. Cummings |
| Summary: | This open-label extension study evaluated the long-term safety and tolerability of idalopirdine 60 mg/day as adjunctive therapy in patients with mild-moderate Alzheimer’s disease (AD). This extension study was a continuation of Studies 1 and 2 of the |
|---|---|
| Item Description: | Gesehen am 19.11.2019 |
| Physical Description: | Online Resource |
| ISSN: | 1875-8908 |
| DOI: | 10.3233/JAD-180595 |